Interleukin 1 (IL1) - Pipeline Review, H1 2018

Interleukin 1 (IL1) - Pipeline Review, H1 2018

Summary

According to the recently published report Interleukin 1 (IL1) - Pipeline Review, H1 2018; Interleukin 1 (IL1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.

The report Interleukin 1 (IL1) - Pipeline Review, H1 2018 outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 6, 1, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Cardiovascular, Immunology, Metabolic Disorders, Oncology, Dermatology, Musculoskeletal Disorders, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Central Nervous System and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Non-Small Cell Lung Cancer, Epidermolysis Bullosa, Inflammation, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Type 2 Diabetes, Acne Vulgaris, Atopic Dermatitis, Autoimmune Disorders, Bladder Cancer, Bullous Pemphigoid, Cancer Anorexia-Cachexia Syndrome, Cardiovascular Risk Factors, Cervical Cancer, Colorectal Cancer, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Inflammatory Bowel Disease, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pain, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Rheumatoid Arthritis, Rhinitis, Sarcoidosis, Skin Inflammation, Skin Ulcers, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
- The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope


List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Interleukin 1 (IL1) - Overview 9
Interleukin 1 (IL1) - Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 15
Products under Development by Universities/Institutes 20
Interleukin 1 (IL1) - Therapeutics Assessment 22
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Interleukin 1 (IL1) - Companies Involved in Therapeutics Development 28
Apexigen Inc 28
Exicure Inc 28
Immune Response BioPharma Inc 28
Moderna Therapeutics Inc 29
Novartis AG 29
Omnitura Therapeutics Inc 30
Opsona Therapeutics Ltd 30
Optimum Therapeutics LLC 31
Peptinov SAS 31
R Pharm 32
Regeneron Pharmaceuticals Inc 32
Spherium Biomed SL 32
Swedish Orphan Biovitrum AB 33
XBiotech Inc 33
Interleukin 1 (IL1) - Drug Profiles 35
AC-203 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
APX-002 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
canakinumab - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
diacerein - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
diacerein CR - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
IR-1000 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IR-1002 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
IR-888 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
LH-026 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
melittin - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
mRNA-2752 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
OMN-54 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
PPV-01 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
rilonacept - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
RPH-104 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
SOBI-006 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
SP-15008 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
suramin hexasodium - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Xilonix - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Interleukin 1 (IL1) - Dormant Products 84
Interleukin 1 (IL1) - Discontinued Products 90
Interleukin 1 (IL1) - Product Development Milestones 93
Featured News & Press Releases 93
Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology 93
Mar 12, 2018: Canakinumab Doesnt Prevent Prediabetes from Progressing to Diabetes 93
Feb 26, 2018: TWi Biotechnology Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa 94
Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 95
Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 96
Jan 15, 2018: Castle Creek Pharmaceuticals Announces Data Validating First Investigators Global Assessment Scale for Epidermolysis Bullosa Simplex Clinical Research 96
Jan 03, 2018: Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit 97
Dec 04, 2017: XBiotech Announces Publication of Phase II Data from Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology 98
Nov 14, 2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions 98
Nov 13, 2017: Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants 99
Nov 13, 2017: Response after Single Treatment with Canakinumab Predicts Which Patients Will Benefit Most 100
Nov 03, 2017: XBiotechs MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions 102
Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting 102
Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America 103
Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer 103
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 105
Disclaimer 106

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018 10
Number of Products under Development by Therapy Areas, H1 2018 11
Number of Products under Development by Indications, H1 2018 13
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 14
Number of Products under Development by Companies, H1 2018 15
Products under Development by Companies, H1 2018 16
Products under Development by Companies, H1 2018 (Contd..1), H1 2018 17
Products under Development by Companies, H1 2018 (Contd..2), H1 2018 18
Products under Development by Companies, H1 2018 (Contd..3), H1 2018 19
Number of Products under Investigation by Universities/Institutes, H1 2018 20
Products under Investigation by Universities/Institutes, H1 2018 21
Number of Products by Stage and Mechanism of Actions, H1 2018 23
Number of Products by Stage and Route of Administration, H1 2018 25
Number of Products by Stage and Molecule Type, H1 2018 27
Pipeline by Apexigen Inc, H1 2018 28
Pipeline by Exicure Inc, H1 2018 28
Pipeline by Immune Response BioPharma Inc, H1 2018 29
Pipeline by Moderna Therapeutics Inc, H1 2018 29
Pipeline by Novartis AG, H1 2018 30
Pipeline by Omnitura Therapeutics Inc, H1 2018 30
Pipeline by Opsona Therapeutics Ltd, H1 2018 31
Pipeline by Optimum Therapeutics LLC, H1 2018 31
Pipeline by Peptinov SAS, H1 2018 31
Pipeline by R Pharm, H1 2018 32
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018 32
Pipeline by Spherium Biomed SL, H1 2018 33
Pipeline by Swedish Orphan Biovitrum AB, H1 2018 33
Pipeline by XBiotech Inc, H1 2018 34
Dormant Products, H1 2018 84
Dormant Products, H1 2018 (Contd..1), H1 2018 85
Dormant Products, H1 2018 (Contd..2), H1 2018 86
Dormant Products, H1 2018 (Contd..3), H1 2018 87
Dormant Products, H1 2018 (Contd..4), H1 2018 88
Dormant Products, H1 2018 (Contd..5), H1 2018 89
Discontinued Products, H1 2018 90
Discontinued Products, H1 2018 (Contd..1), H1 2018 91
Discontinued Products, H1 2018 (Contd..2), H1 2018 92

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018 10
Number of Products under Development by Therapy Areas, H1 2018 11
Number of Products under Development by Top 10 Indications, H1 2018 12
Number of Products by Mechanism of Actions, H1 2018 22
Number of Products by Stage and Mechanism of Actions, H1 2018 22
Number of Products by Routes of Administration, H1 2018 24
Number of Products by Stage and Routes of Administration, H1 2018 24
Number of Products by Molecule Types, H1 2018 26
Number of Products by Stage and Molecule Types, H1 2018 26

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018According to the recently

USD 3500 View Report

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018According to the recently published report Interleukin 2 Receptor Subunit Alpha - Pipeline

USD 3500 View Report

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen

USD 3500 View Report

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2018

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2018Interleukin 1 Receptor Type

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available